BusinessCIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque PsoriasisBy Nasdaq OMXOct 3, 2016, 6:00 AM UTC
BusinessDermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology CongressBy Nasdaq OMXOct 1, 2016, 7:05 AM UTC
BusinessDermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology CongressBy Nasdaq OMXSep 28, 2016, 11:30 AM UTC
BusinessDermira Licenses DRM04 to Maruho for Hyperhidrosis in JapanBy Nasdaq OMXSep 20, 2016, 8:05 PM UTC
BusinessDermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from TakedaBy Nasdaq OMXSep 12, 2016, 11:30 AM UTC
